New Study Shows How Genes Control Blood Proteins Important To Health
A new study shows how genes control levels of many blood proteins implicated in disease. The findings are the result of an international collaboration between scientists at the University of Exeter, the National Institute on Aging, and the Tuscany and Florence Health Agencies.
Blood Free Monitoring As Good As Blood Tests In Predicting The Course Of AIDS
Researchers at the University of Pennsylvania School of Medicine have shown that monitoring treatment adherence to AIDS therapy is a simple blood-free way to monitor risk of disease progression. The international study was published in the May issue of the journal PLoS Medicine.
Mortality During Sepsis Reduced By Ashwell Receptor
In research that solves the longest-standing mystery in glycobiology - a field that studies complex sugar chains called glycans - researchers at the University of California, San Diego School of Medicine have discovered that a molecule in the liver of all animals, called the Ashwell receptor, is critical in helping the body fight off the abnormal and lethal blood clotting caused by bacterial infection.
Making A Fist Of Blood Taking - And Ending Up In Casualty
A paper in the latest issue of the Annals of Clinical Biochemistry shows how the manner in which blood is collected from patients for some blood tests alters the results of those tests when it comes to analysis. Clenching the fist during blood taking could land some patients in their nearest A&E department being monitored for a heart emergency.
Catalyst Biosciences Selects Drug Development Candidate In Factor VIIa Program For Hemophilia
Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients.
New Formulation Of Medication For Rare Disease Patients
A new treatment option - Ferriprox Oral Solution - is now available to patients suffering from thalassaemia major, a rare genetic disease with only 50 percent of the patients surviving the age of 35 years1. Thalassaemia patients require blood transfusions to survive, which leads to damaging iron accumulation in the tissues, especially the heart.
Lev Pharmaceuticals Announces Cinryze TM Complete Response Submission Accepted For Review By FDA
Lev Pharmaceuticals, Inc. (OTCBB: LEVP.OB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review Lev's complete response submission for Cinryze™ (C1 inhibitor), the Company's lead product candidate. Lev is seeking marketing approval for Cinryze™
Heart Attack Injury Lessened And Function Restored By Naturally-Occuring Protein
Medical College of Wisconsin researchers in Milwaukee have shown for the first time that thrombopoietin (TPO), a naturally occurring protein being developed as a pharmaceutical to increase platelet count in cancer patients during chemotherapy, can also protect the heart against injury during a heart attack.
ParagonDx Receives FDA 510 k Marketing Clearance For Warfarin Sensitivity Genotyping Kit
ParagonDx, a leader in genetic testing diagnostics, has received 510(k) marketing clearance from the US Food and Drug Administration (FDA) for its in vitro diagnostic test. The Rapid Genotyping Assay is to be used to detect the presence of variations in the genes CYP2C9 and VKORC1.
Nix Essential To Red Blood Cells
A process of self-digestion called autophagy prompts the maturation of red blood cells. Without a protein called Nix, the cells would not effectively rid themselves of organelles called mitochondria and consequently become short-lived, leading to anemia, said researchers at Baylor College of Medicine in Houston in a report that appears online in the journal Nature.